All Drug Development articles – Page 9
-
NewsHow nanocarriers and VLPs are uniting to fight cancer
Innovations in nanomedicine are merging to redefine precision oncology. From virus-like particles to magnetic nanoparticles, integrated delivery systems are showing powerful potential for new, targeted cancer treatments.
-
NewsSperm ‘switch’ discovery could lead to new fertility therapies
Scientists have discovered the molecular ‘switch’ that powers sperm for fertilisation, which could potentially lead to new infertility treatments.
-
NewsNew gene therapy restores brain function in SYNGAP1 disorder
Scientists have developed a new gene therapy that reversed symptoms of SYNGAP1-related brain disorders in mice, which could lead to new treatments for this group of neurological conditions.
-
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
-
NewsNew UCLA drug could restore heart and organ function
UCLA researchers have developed a monoclonal antibody, AD-NP1, that blocks ENPP1 to enhance heart repair and reduce scar tissue.
-
NewsDDHD2 enables neurons to synthesise and burn fat for energy
Scientists have discovered that neurons can burn and make their own fats for energy – a finding that could lead to new treatments for rare and currently untreatable brain diseases.
-
ArticleAdvancing gene editing: the role of lipid nanoparticles in CRISPR delivery
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
-
NewsPemafibrate and telmisartan combo may reverse fatty liver
A new study shows that approved drugs, pemafibrate and telmisartan, when combined, can reduce liver fat and may lower cardiovascular risk in metabolic dysfunction-associated steatotic liver disease.
-
NewsTargeting EZH2 may prevent triple-negative breast cancer spread
A new study has revealed that the enzyme EZH2 triggers abnormal cell division that fuels metastasis, and blocking this enzyme with existing drugs could restore normal cell behaviour to stop cancer from spreading.
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.
-
NewsCloneSeq-SV: new blood test tracks ovarian cancer recurrence
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
-
NewsNew CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
-
ArticleFast-tracking advanced therapies without compromising regulatory success
Early planning for potency CQAs, comparability and evolving global regulations can set advanced therapies on the fastest path to approval. Dr Christian Schneider shares how to prepare from the start to accelerate development without compromising the evidence regulators expect.
-
NewsSenolytic drug combo boosts cancer immunotherapy and reduces side effects
Researchers have discovered that targeting immune cell ageing can overcome resistance to head and neck cancer treatment.
-
ArticleFrom data to therapy: emerging tech driving cancer drug discovery
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
-
NewsProtecting bones from cancer damage: targeting the UPR pathway
New research highlights how cancer hijacks the unfolded protein response (UPR) in bone cells – potentially allowing for the development of therapies that target this pathway to prevent fractures.
-
ArticleInside Zasocitinib: a new model for TYK2 inhibition in immune-mediated diseases
Zasocitinib is a highly selective, investigational TYK2 inhibitor developed to target immune-mediated diseases with fewer off-target effects than traditional JAK inhibitors. This article explores its mechanism, selectivity data and clinical progress.
-
NewsThe road to safer painkillers: the role of the EP2 receptor
NYU researchers have identified a receptor in prostaglandins that triggers pain without affecting inflammation – which could lead to safer, more targeted pain treatments.
-
NewsMarine sponges could hold the key to new Leishmaniasis treatments
Japanese researchers have discovered potent new compounds from marine sponges that could transform the treatment of leishmaniasis – a neglected tropical disease affecting millions worldwide.
-
ArticleThe science behind the systematic discovery of molecular glues
For decades, molecular glues have been stumbled upon rather than designed. A new scientific approach is now changing that – expanding what is considered druggable.